Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Journal: Lancet regional health. Americas
Published: March 25, 2026
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.
Journal: Frontiers in oncology
Published: January 12, 2026
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.
Journal: Clinical lung cancer
Published: August 19, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.
Journal: Frontiers in medicine
Published: January 11, 2025
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Journal: Radiology
Published: August 20, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Journal: JTO clinical and research reports
Published: February 21, 2024
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Journal: Targeted oncology
Published: August 03, 2023
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Journal: The oncologist
Published: July 27, 2023
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Journal: Future oncology (London, England)
Published: June 15, 2023
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 25, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Journal: The Lancet. Oncology
Published: January 25, 2022
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Journal: Future oncology (London, England)
Published: November 16, 2021
Last Updated: 09/26/2026